No Data
No Data
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $75 to $120
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Disc Medicine Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120
Disc Medicine Analyst Ratings
Disc Medicine's Promising Position in MF Anemia Treatment: Buy Rating Affirmed by Evan Seigerman